Accelerating Drug Development using OligonucleotidesSince its discovery, RNA interference (RNAi) technology has been widely recognized as a novel drug development platform that could change the paradigm of therapeutic development.OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics based on the science of RNAi to address a wide variety of illnesses. The Company has developed core platforms (asymmetric siRNA, cell-penetrating asiRNA) targeting locally administrable diseases, such as hypertrophic scars, hair loss, and age-related macular degeneration (AMD). OliX's third RNAi therapeutic platform, GalNAc-asiRNA, targets multiple liver diseases, including NASH/diabetes and HBV.For the general welfare of human beings, OliX is constantly endeavoring to become a leader in the global biotechnology industry by innovating and expanding its pipeline, even to the undruggable diseases.